A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

At the recent ATTD 2025 meeting, participants discussed recent progress and remaining challenges in developing a fully closed ...

The Chief Executive of Eli Lilly has told the BBC that he is doubtful tariffs could bring manufacturing jobs to the US whilst ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

The stock market has been on edge since the announcement of tariffs, reporting its biggest loss since March 2020. The damage ...

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

But at the same time, industry leaders are bracing for the news that they think is inevitable given Trump’s declaration in February to impose “25% or higher” levies on imported drugs.

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...